Aypar, EdaIzzettin, FİKRET VEHBİAki, Sahika ZeynepSANCAR, MESUTYegin, Zeynep ArzuTurkoz-Sucak, Gulsan2020-10-292020-10-292018-06-01Aypar E., Izzettin F. V. , Aki S. Z. , SANCAR M., Yegin Z. A. , Turkoz-Sucak G., -Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib-, JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, ss.281-289, 2018http://hdl.handle.net/20.500.12645/25449Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.ArticleWOS:0004320895000058504675115310.1177/1078155217697486